How a gut-linked immune signal (IL-17) may influence Alzheimer's
Dissecting the modulatory functions of interleukin-17 in Alzheimer's Disease
Researchers are looking at whether an immune protein called IL-17, shaped by gut bacteria and immune cells, can affect Alzheimer's disease in older adults.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11456943 on NIH RePORTER |
What this research studies
From my point of view, the team is focusing on a specific immune signal called interleukin-17 (IL-17) and immune cells known as Th17 that can be influenced by gut bacteria. They plan to track how gut microbes and these immune responses might change brain health related to Alzheimer’s, using laboratory experiments and disease models alongside information from people with AD. The work aims to connect gut changes, peripheral immune activity, and Alzheimer-related brain changes to understand steps that lead to symptoms. This is early-stage research meant to reveal how these pieces fit together so better therapies could be designed later.
Who could benefit from this research
Good fit: People living with Alzheimer’s disease or older adults at high risk for AD (for example, those with AD-related pathology or symptoms) would be the most relevant group for this work.
Not a fit: People with non‑Alzheimer dementias or those seeking immediate symptom relief are unlikely to benefit directly from this basic/mechanistic research in the short term.
Why it matters
Potential benefit: If successful, the project could point to new ways to slow or prevent Alzheimer’s by targeting IL-17, Th17 cells, or gut-immune interactions.
How similar studies have performed: Prior research has linked immune activity and gut microbes to brain health and Alzheimer’s, but the specific role of IL-17 and Th17 cells is relatively novel and less well established.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Huh, Jun R. — Harvard Medical School
- Study coordinator: Huh, Jun R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.